Acuity Brands vs Outlook Therapeutics

Acuity Brands (AYI) and Outlook Therapeutics (OTLK) are two companies that operate in the healthcare sector. Acuity Brands is a leading provider of lighting solutions, while Outlook Therapeutics focuses on developing and commercializing innovative treatments for eye diseases. Both companies have shown strong performance in recent years, however, they cater to different markets and have distinct business models. Investors looking to diversify their healthcare portfolio may find opportunities in these two stocks.

Acuity Brands or Outlook Therapeutics?

When comparing Acuity Brands and Outlook Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Acuity Brands and Outlook Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Acuity Brands has a dividend yield of 0.19%, while Outlook Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Acuity Brands reports a 5-year dividend growth of 0.00% year and a payout ratio of 4.31%. On the other hand, Outlook Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Acuity Brands P/E ratio at 22.73 and Outlook Therapeutics's P/E ratio at -1.26. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Acuity Brands P/B ratio is 4.04 while Outlook Therapeutics's P/B ratio is -1.42.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Acuity Brands has seen a 5-year revenue growth of 0.38%, while Outlook Therapeutics's is -1.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Acuity Brands's ROE at 19.11% and Outlook Therapeutics's ROE at 146.56%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $304.19 for Acuity Brands and $4.95 for Outlook Therapeutics. Over the past year, Acuity Brands's prices ranged from $156.84 to $312.20, with a yearly change of 99.06%. Outlook Therapeutics's prices fluctuated between $4.61 and $18.00, with a yearly change of 290.46%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.